Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients
Eun‐Jung Jung(The University of Texas MD Anderson Cancer Center), George A. Călin(The University of Texas MD Anderson Cancer Center), Libero Santarpia(Endocrine Society), Robert C. Bast(The University of Texas MD Anderson Cancer Center), Aman U. Buzdar(Nottingham City Hospital), Xiao‐Feng Le(The University of Texas MD Anderson Cancer Center), Erica Moretti(Hospital of Prato), Francisco J. Esteva(The University of Texas MD Anderson Cancer Center), Ju‐Yeon Kim(Gyeongsang National University), Soon‐Tae Park(Gyeongsang National University), Angelo Di Leo(National Cancer Center), Lajos Pusztai(Yale Cancer Center)
Cited by 291
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
|Cancer Cell|2004|1.9k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
|Journal of Clinical Oncology|2007|1.6k
Noncoding RNA therapeutics — challenges and potential solutions
|Nature Reviews Drug Discovery|2021|1.5k